Spyre Therapeutics (SYRE)

• Market cap: $7.67B
• 1 day: 0.97%
• 5 days: 8.94%
• 1 month: 26.06%
• 3 months: 105.16%
• 6 months: 163.94%
• Year to date: 188.88%
• 1 year: 485.81%
• 5 years: -45.13%
• 10 years: -20.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Employees: 112